Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.39 USD | +0.32% |
|
+4.83% | +25.51% |
May. 29 | Catalent Shareholders Approve Deal With Novo Holdings | MT |
May. 29 | Catalent stockholders approve deal with Novo Holdings | RE |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's enterprise value to sales, at 3.38 times its current sales, is high.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.51% | 10.21B | C | ||
+45.82% | 765B | C+ | ||
-6.16% | 354B | C+ | ||
+19.86% | 331B | B- | ||
+9.32% | 299B | C+ | ||
+18.87% | 248B | B+ | ||
-1.60% | 219B | A+ | ||
+11.10% | 216B | B- | ||
+5.90% | 164B | C+ | ||
-0.73% | 162B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CTLT Stock
- Ratings Catalent, Inc.